Leo Pharmas innovationsarm poster flere penge i digital screening

Et hollandsk selskab har sikret sig den tredje investering fra Leo Pharmas digitale innovationsafdeling, der har fattet interesse i selskabets app til screening for hudkræft. "Jeg ser enormt potentiale i løsninger som denne,” siger Kristian Hart-Hansen, adm. direktør for Leo Pharma Innovation Lab.

Photo: /Ritzau Scanpix/Emil Hougaard

Sammen med en række andre investorer har Leo Pharma Innovation Lab postet ekstra 7,6 mio. dollar (cirka 48 mio. kr.) i en ny kapitalrejsningsrunde for det Amsterdam-baserede selskab Skinvision.

Officielt er det Leo Pharma, som har postet penge i selskabet, men i praksis er det Innovation Lab, Leo Pharmas digitale innovationsenhed under adm. direktør Kristian Hart-Hansen, som tager sig af investeringen.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from AMWatch

Danish FSA issues warning over SFDR implementation

The Danish FSA, Finanstilsynet, states that asset managers are using the EU’s sustainable finance disclosure regulation to signify quality, which is not the point of the legislation. In fact, the FSA states it is the opposite of what the EU intended.

Related articles

Latest news

AMWatch job

See all jobs

See all jobs

Watch job

See all jobs

See all jobs

Latest news from FinansWatch (dk)

Latest news from EnergyWatch

Latest news from ShippingWatch